

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, PO Box 1450
Alexandria, VA 22313-1450, on October 28, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti Appling



Attorney Docket No. 407T-980910US
Client Ref. No. 2000-168-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Glenn L. Millhauser, et al.

Application No.: 09/851,586

Filed: May 8, 2001

For: METHODS AND COMPOUNDS FOR
MODULATING MELANOCORTIN
RECEPTOR LIGAND BINDING
AND ACTIVITY

Examiner: Carolyn L. Smith

Art Unit: 1631

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action. Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/851,586
Filing Date	May 8, 2001
First Named Inventor	Glenn L. Millhauser
Group Art Unit	1631
Examiner Name	Carolyn L. Smith
Attorney Docket Number	407T-980910US
Date Submitted	October 28, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
1	5,622,860			Yamada et al	04/22/1997	
2	5,703,220			Yamada et al	12/30/1997	
3	5,731,408			Hadley et al	03/24/1998	
4	5,766,877			Stark et al	06/16/1998	
5	5,817,787			Yamada et al	10/06/1998	
6	5,843,652			Woychik	12/01/1998	
7	5,869,257			Yamada et al	02/09/1999	
8	5,932,779			Lee et al	08/03/1999	
9	5,994,087			Cone et al	11/30/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal	T
		Office	Number	Kind Code (if known)				
10	WO	99/43709						
11	WO	99/64002			Merk & Co.	12/16/1999		
12	WO	99/57148			WA Pharm AB	11/11/1999		
13	WO	99/55679			Trega Biosciences	11/04/1999		
14	WO	99/55832			Merk & Co.	11/04/1999		
15	WO	99/54358			Quadrant Holdings	10/28/1999		
16	WO	99/43709			Regents of the University of CA	09/02/1999		
17	WO	99/31508			Merk & Co.	06/24/1999		
18	WO	99/21571			Trega Biosciences	05/06/1999		
19	WO	98/56914			Oregon Health Sci	12/17/1998		
20	WO	98/10068			Oregon Health Sci	03/12/1998		
21	WO	97/43412			Amgen Inc.	11/20/1997		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/851,586
		Filing Date	May 8, 2001
		First Named Inventor	Glenn L. Millhauser
		Group Art Unit	1631
		Examiner Name	Carolyn L. Smith
		Attorney Docket Number	407T-980910US
		Date Submitted	October 28, 2004

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	22	Fakete <i>et al.</i> (2004) Endocrinology, online publication: doi:10.1210/en.2004-0476	
	23	Fong, <i>et al.</i> (1997) <i>Biochem. Res. Commun.</i> 237:629 611	
	24	Jackson <i>et al.</i> (2002) <i>Biochemistry</i> , 41: 7565-7572	
	25	Kiefer <i>et al.</i> (1997) <i>Biochemistry</i> 36: 2084-2090	
	26	Kiefer <i>et al.</i> (1998) <i>Biochemistry</i> 37: 991-997	
	27	Klebig, <i>et al.</i> , (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:4728-4732	
	28	Michaud, <i>et al.</i> (1997) <i>J. Endocrinol</i> 155:207-209	
	29	PEP-NET (1999) 12(3): 1-4.	
	30	Quillan <i>et al.</i> (1998) <i>FEBS Lett.</i> 428, 59-62.	
	31	Willard <i>et al.</i> (1995) <i>Biochemistry</i> 34: 12341-12346.	
	32	Yang <i>et al.</i> (1999) <i>Mol. Endocrinol.</i> 13: 148-155.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.